Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
Stable peripheral arterial disease guideline
This guideline was developed by a multidisciplinary expert panel: Begg A et al with the support of a grant from Bayer plc.
Stable coronary artery disease guideline
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
SIGN antithrombotics guideline
A clear SIGN guideline summary exploring antiplatelet and anticoagulant agents and indications for their use, including cardiac and cerebrovascular disease.
Resource hub
Practical guide to recording ankle brachial pressure index (ABPI)
- Previous
- Next
Educational resources
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for eligible patients with DVT or PE*
Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Please see the bottom of the page for full disclaimer.
Community Pharmacist Counselling Checklist for patients with NVAF initiated on Xarelto▼ (rivaroxaban)
Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines for Pharmacy. Please see the bottom of the page for full disclaimer.
Xarelto▼ (rivaroxaban) patient counselling checklist for HCPs—initiating, or transitioning to rivaroxaban for stroke prevention in patients with NVAF*
Information intended for healthcare professionals. This checklist was developed from content provided by Bayer plc and the format was developed by Guidelines. Please see the bottom of the page for full disclaimer.
Consensus guideline on the holistic management of patients requiring anticoagulation
This guideline was developed by a multidisciplinary expert panel: Fay M et al with the support of a grant from Bayer plc.
NICE Technology Appraisal 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information.